Endostatin is a novel antiangiogenic agent currently in phase I trials. In the context of this trial, we are evaluating the use of non-invasive imaging with PET to determine the relationship between tumor blood flow and glucose metabolism in imaged tumors from treated patients.
C Charnsangavej合作论文数1NA MULLANI合作论文数1KL Gould合作论文数1Ht Tran合作论文数1Jl Abbruzzese合作论文数1
Roy S. Herbst合作论文数Yale Cancer Center, School of Medicine, Yale University1B J Barron合作论文数1Lamk Lamki合作论文数Departments ofClinical Immunology and Biological Therapy;Hospital and Tumor Institute;Departments ofClinical Immunology and Biological Therapy, Hospital and Tumor Institute1
